Extended Data Fig. 5: VEGF mRNA LNP 55 improves maternal weight and serum concentration of inflammatory cytokines in inflammation-induced pre-eclampsia.
From: Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia
Inflammation-induced pre-eclampsia was established through i.p. administration of 1 µg kg−1 lipopolysaccharide (LPS) on gestational day E7.5. 1 mg kg−1 VEGF mRNA LNP 55 was then administered i.v. on gestational day E11. a–c, Change in maternal weight was measured daily (a), and on gestational day E17 (b,c) fetal and placental weight were recorded. d–j, Serum levels of (d) VEGF, (e) sFlt-1, (f) alanine transaminase (ALT), (g) aspartate aminotransferase (AST), (h) tumour necrosis factor (TNF), (i) interleukin-6 (IL-6), and (j) interferon-γ (IFNγ) were evaluated on gestational days E11.5 and E17. k, Mean blood vessel area in the placental labyrinth was quantified from H&E-stainined placental sections. Maternal weight change and serum protein levels are reported as the mean ± s.e.m. (n = 8 biological replicates). Fetal and placental weight are reported as the median with the 25th and 75th percentiles (n = 8 biological replicates, 6–9 fetuses or placentas per mouse). Mean blood vessel area is reported as the median with the 25th and 75th percentiles (n = 8 biological replicates, 1–2 placentas per mouse, 2 sections per placenta, 2–3 images per section). Ordinary two-sided, two-way (a, d–j) or nested two-sided, one-way (b–c, k) ANOVAs with post hoc Student’s t tests using the Holm-Šídák correction for multiple comparisons were used to compare responses across treatment groups.
